Sun Pharma Secures Interim Win in Trademark Dispute
Sun Pharmaceutical Industries has secured interim relief from the Bombay High Court in a trademark dispute, strengthening its position in protecting branded pharmaceutical products.
Author
Senior writer, legal and rare disease markets
Imogen Reyes covers pharmaceutical litigation, settlements and patent disputes for PharmaWire, and writes its long-form rare disease market guides.
Sun Pharmaceutical Industries has secured interim relief from the Bombay High Court in a trademark dispute, strengthening its position in protecting branded pharmaceutical products.
A Pennsylvania federal court has delivered a mixed ruling in a major generics antitrust case, allowing key claims to proceed against Novartis and its former subsidiary Sandoz, while dismissing others.
California’s highest court is weighing a case that could reshape how far pharmaceutical companies are expected to go in developing improved medicines, with early signals suggesting caution around imposing a legal “duty to innovate.”
The $7.4bn settlement between OxyContin manufacturer Purdue Pharma, its Sackler family owners and US states has taken legal effect, marking a long-awaited resolution to one of the most consequential corporate liability cases in modern…
Novo Nordisk has asked a Texas federal court to dismiss an antitrust lawsuit alleging it attempted to limit competition in the GLP-1 weight-loss drug market.
A Philadelphia jury has begun deliberating in a medical malpractice case concerning the 2019 death of 26-year-old Matthew Tarnopol.
The Supreme Court of the United States has heard oral arguments in the ongoing dispute between Hikma Pharmaceuticals and Amarin Pharma, focusing on the legal boundaries of marketing generic drugs under a “skinny label.”
An update in the ongoing opioid litigation involving Purdue Pharma shows that the state of Oregon is set to receive $65.6 million as part of a wider $7.4 billion settlement linked to the opioid crisis.
A federal judge has dismissed part of a lawsuit brought by Eli Lilly against Empower Pharmacy, marking a partial setback in the company’s effort to challenge the sale of compounded versions of its GLP-1 drugs.
The Supreme Court of the United States is set to hear a case that could affect how quickly lower-cost generic drugs reach patients. The dispute, known as Hikma v. Amarin, involves Hikma Pharmaceuticals and Amarin over a heart disease drug…
Pharmaceutical company Merz has secured a key legal victory in its ongoing dispute over its multiple sclerosis drug Fampyra. The Court of Appeal of the Unified Patent Court (UPC) has overturned an earlier decision and granted a preliminary…
The High Court in Kuala Lumpur has dismissed an application by Techno Secure Print Sdn Bhd seeking permission to initiate judicial review proceedings against the Health Ministry over a terminated pharmaceutical tender.
In a significant development in long-running opioid litigation, Purdue Pharma has been sentenced to pay $5.5 billion in fines and penalties following its 2020 guilty plea in connection with the marketing of its opioid drug, OxyContin. The…
A federal court in North Dakota has ruled that a state law aimed at expanding access to discounted medications is unconstitutional. In a written order, Daniel Traynor held that House Bill 1473 violates federal law and exceeds the state’s…
It has been confirmed today that Pfizer settled with the final defendant, Hikma Pharmaceuticals.
Update from the Vyndamax (tafamidis) trial: Hikma Pharmaceuticals, the holdout defendant, no longer appears to be challenging the validity of Pfizer’s patent.
BREAKING - Pfizer (PFE) SETTLES Tafamidis suit with two of three defendants. Key question for analysts - how long will Pfizer’s patent protection last under the settlement? Based on available research, generics could be out of the market…
Analysts are looking ahead to the tafamidis patent trial involving Pfizer (NYSE: PFE), as recent court developments begin to shape investor expectations ahead of the proceedings next week.
A court case between Pfizer (PFE) and generic drug manufacturers, which will determine control of the $16.5 billion-plus Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, is less than two weeks away.